Following a full submission
zoledronic acid 5mg solution for infusion (Aclasta®) is accepted for restricted use within NHS Scotland for treatment of osteoporosis in post-menopausal women at increased risk of fractures. Intravenous zoledronic acid is restricted to use in patients who are unsuitable for or unable to tolerate oral treatment options for osteoporosis. Treatment initiation should be under specialist supervision.
This preparation is licensed for administration once a year and has been shown to reduce the incidence of vertebral and hip fractures over 3 years compared with placebo.
Download detailed advice66KB (PDF)
- Medicine name:
- zoledronic acid (Aclasta)
- SMC ID:
- Treatment of osteoporosis in postmenopausal women at increased risk of fractures.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Date advice published
- 10 March 2008